A series of the first 13 combined Magseed and Magtrace cases in a single centre in regional Victoria

Abstract

AbstractBackgroundThe standard journey for a patient with impalpable breast cancer wishing to undergo breast‐conserving surgery involves placement of a guidewire and lymphoscintigraphy pre‐operatively. Access to these procedures is limited in the regional centres, this scheduling can require overnight stays away from home and can delay theatre which can increase patient distress. The Sentimag technology uses magnetism for localisation of preoperatively inserted Magseeds (for impalpable breast lesions) and Magtrace (for sentinel node biopsy), avoiding guidewire placement and nuclear medicine. This study evaluates the first 13 cases using this combined technique by a single specialist breast surgeon in a regional centre.MethodsThirteen consecutive patients were enrolled with ethics approval. Magseeds were placed under ultrasound guidance preoperatively, and Magtrace was injected at the time of pre‐operative consultation.ResultsThe median age of patients was 60 (range 27–78). The average distance from hospital was 81.63 km (2.8–238 km). The average operating time was 1h54m (range 1 h 17 m–2 h 39 m) and the mean total journey time was 8h54m (range 6–23 h). The earliest time‐out was 8:40 am. Re‐excision rate was 23% (n = 3), however, in each re‐excision case the lesions were in the axilla, were small (<15 mm) and were in patients with dense breasts on mammography. There were no significant adverse outcomes.ConclusionIn this preliminary study Sentimag localisation appears to be safe and reliable when used in combination. Re‐excision rates were only slightly higher than reported in the literature and predicted to downtrend with ongoing learning curve.